Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
6Customers
3Debt Items
5Related Chains
Source-Backed Evidence Depth
Imunon, Inc. (IMNN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
4Distinct source URLs
7High confidence
0.791Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Imunon, Inc. Suppliers
Ticker
Name
Confidence
Evidence
DUKE-UNIVERSITY
DUKE-UNIVERSITY
92%
we are party to license agreements with Duke University, under which we have exclusive rights to commercialize medical treatment products and procedures based on Duke’s thermo-sensitive liposome technology
H-C-WAINWRIGHT-CO-LLC
H-C-WAINWRIGHT-CO-LLC
92%
The Company previously registered the offer and sale of up to $10,000,000 of shares of Common Stock through the Sales Agent under the Sales Agreement.
STREETERVILLE-CAPITAL-LLC
STREETERVILLE-CAPITAL-LLC
92%
Imunon, Inc. entered into a securities purchase agreement with Streeterville Capital, LLC, providing for the issuance and sale by the Company, and the purchase by the Investor, of Series A Preferred …
in infectious diseases. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase II clinical develop…
Reciprocal relationship from HRZN graph: Reciprocal relationship from IMNN graph: in infectious diseases. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized…
ARCADIA-SECURITIES-LLC
ARCADIA-SECURITIES-LLC
62%
in infectious diseases. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase II clinical develop…
CLSN-LABORATORIES-INC
CLSN-LABORATORIES-INC
62%
ial items; uncertainties and assumptions regarding the potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U.S. and worldwide res…
CO-LLC
CO-LLC
62%
in infectious diseases. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase II clinical develop…
NASDAQ-STOCK-MARKET-LLC
NASDAQ-STOCK-MARKET-LLC
62%
, and contract research organizations may engage in fraudulent conduct or other illegal activity. Misconduct by those parties could include intentional, reckless and/or negligent conduct or disclosur…
Imunon, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
IMNN-DEBT
Debt stack $6.1M
90%
Market cache reports total debt of $6.1M.
IMNN-DEBT-10245
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2017-12-31.
IMNN-DEBT-10244
Warrants outstanding: 4059
90%
xbrl warrant detail from xbrl 2025-12-31.
Imunon, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Imunon, Inc..
Imunon, Inc. Ownership
Holder
Name
Confidence
Evidence
IMNN-OWNER-OSAIC-HOLDINGS-INC
OSAIC HOLDINGS, INC.
90%
13F overlay lists OSAIC HOLDINGS, INC. as top holder; 3 tracked holders.
